News Posts List
Cancer Genetics (CGIX) to Present Positive Data from UroGenRA-Kidney Test
02/25/2014
Cancer Genetics, Inc. (Nasdaq: CGIX) announced that new data that further validates its UroGenRA-Kidney diagnostic test for renal cell cancer...
Advanced age should not preclude sunitinib use for mRCC
02/24/2014
Elderly kidney cancer patients benefit from sunitinib therapy just as much as their younger counterparts, a retrospective analysis of six clinical trials shows.
Stephen Blackwood: ObamaCare and My Mother's Cancer Medicine
02/24/2014
The news was dumbfounding. She used to have a policy that covered the drug that kept her alive. Now she's on her own.
Altering sunitinib dosing schedule improves tolerability
02/23/2014
Shortening the time that patients with advanced renal cell carcinoma are on and off treatment with sunitinib improves the drug’s overall tolerability without affecting its efficacy, say Japanese researchers.
Comparative outcomes of everolimus, temsirolimus and sorafenib as second targeted therapies
02/20/2014
To compare outcomes of metastatic renal cell carcinoma (mRCC) patients treated with everolimus, temsirolimus, and sorafenib following initial treatment with a tyrosine kinase inhibitor (TKI) in community and academic practices throughout the US.
Kidney cancer care improves with vaccine-based approach
02/20/2014
The Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute has opened a novel Phase III, vaccine-based clinical trial aimed at providing kidney cancer patients long-term control of their disease.
Sunitinib safe, effective in patients with mRCC, renal insufficiency
02/14/2014
Sunitinib demonstrated encouraging activity and manageable toxicities in patients with metastatic renal cell carcinoma and renal insufficiency, according to study results.
Is yours a "junk" health plan? Obamacare may say it is, but perhaps not.
02/13/2014
According to The Heritage Foundation, Obamacare disrupts nearly all areas of health care. Governed by an independent Board of Trustees, The Heritage Foundation is an independent, tax-exempt institution.
Clinical Trials and Health Insurance Coverage
02/12/2014
New patient information is now available on Cancer.Net about the coverage of costs for research study participation under the Affordable Care Act (ACA), which now requires health insurance companies to cover routine costs associated with approved clinical trials.
Vitreous Hemorrhage as the Initial Sign of Renal Cell Carcinoma Metastasis
02/11/2014
Choroidal metastases generally appear as a solitary, yellow- or orange-colored mass in the macula or perimacular region of the eye. In an analysis of 520 eyes with uveal metastasis, the tumor appeared as a solitary mass (71%) with mean basal dimension of 9 mm and mean thickness of 3 mm.1 In that analysis, associated findings included subretinal fluid (73%) and retinal pigment epithelial alterations (57%). Hemorrhage is an unusual finding with choroidal metastatic disease. Single case reports have highlighted this rare association.
News Feed